Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
Eleanor Williams, Jana Bagarova, Georgina Kerr, Dong-Dong Xia, Elsie Place, Devaveena Dey, Yue Shen, Geoffrey A. Bocobo, Agustin H. Mohedas, Xiuli Huang, Philip E.J. Sanderson, Arthur M. Lee, Wei Zheng, Aris N. Economides, James C. Smith, , Alex N. Bullock
The paper identifies saracatinib as a potent ALK2 inhibitor effective in preventing heterotopic ossification in FOP models.
JCI Insight · Mar 11, 2021Peer-reviewedMolecular Biology